The world’s first comprehensive
genetic screen for reproductive health
Defining a new category of genetic tests
Unlike carrier screening tests, which look at the health risks for a baby, the Fertilome test is the first genetic screen that examines a woman’s genetic signature and how it may impact her reproductive health and ability to conceive, today and in the future.
How the Fertilome test can work for you
By revealing genetic risk factors, the Fertilome test enables more refined diagnoses and treatment decisions than physical examinations or existing diagnostic tests alone. Using the genetic test can help you frame conversations around reproductive health and family building as a proactive journey.
Identify subclinical factors
Refine treatment plans
Counsel women with family history
Counsel egg freezing candidates
Guide targeted lifestyle counseling
The science behind our test
The Fertilome test analyzes 49 variants in 32 genes associated with a spectrum of female reproductive conditions. The Fertilome panel was developed through a systematic literature review and statistical meta-analysis.
Take the next step
1. https://clinicalgenome.org/site/assets/ les/2657/current_clinical_validity_classi cations.pdf
2. The Fertilome test was developed and its performance characteristics determined by Celmatix Clinical Laboratories, a laboratory regulated under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical testing and the test has been analytically validated in accordance with CLIA standards. Fertilome has not been cleared or approved by the US Food and Drug Administration. At this time, physicians of NY, FL, MD, RI, PA, and CA residents may request Fertilome under New York State Department of Health's NPL process.